Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 4/20 | 0.54 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.54 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | CD69 | Q07108 | 1/20 | 0.47 |
| ▸ | BDNF | P23560 | 3/20 | 0.46 |
| ▸ | PTN | P21246 | 2/20 | 0.46 |
| ▸ | MDK | P21741 | 2/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | HPSE | Q9Y251 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.42 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.42 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | SERPINC1 | P01008 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20390684 | 0.93 | CD69 (0.53) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL20390670 | 0.93 | CD69 (0.53) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL30089382 | 0.91 | BDNF (0.51) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL30089381 | 0.91 | LGALS3 (0.49) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL30089448 | 0.90 | CD69 (0.52) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL20390719 | 0.89 | CD69 (0.50) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL20390696 | 0.89 | CD69 (0.50) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL20390690 | 0.88 | LGALS3 (0.47) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL16623683 | 0.88 | LGALS3 (0.47) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL14597949 | 0.88 | LGALS3 (0.47) | LGALS3LGALS8LGALS4MAPK1CD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4483187-B1 | A METHOD FOR DIAGNOSIS OF TRAUMATIC BRAIN INJURY | MEDICORTEX FINLAND OYJ (FI) | 2025-12-03 | — | — | EP | disclosed |
| US-12455286-B2 | Cytometric assays | THE MEDICAL RESEARCH, INFRASTRUCTURE, AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER (IL) | 2025-10-28 | — | — | US | disclosed |
| US-20250195689-A1 | GLYCOMIMETIC LIGANDS | AVICEDA THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| US-20250172573-A1 | A METHOD FOR DIAGNOSIS OF TRAUMATIC BRAIN INJURY | MEDICORTEX FINLAND OY (FI) | 2025-05-29 | — | — | US | disclosed |
| US-20250120976-A1 | BIOMARKERS OF METHOTREXATE-INDUCED IMMUNE TOLERANCE | GENZYME CORPORATION | 2025-04-17 | — | — | US | disclosed |
| US-12213979-B2 | Biomarkers of methotrexate-induced immune tolerance | GENZYME CORPORATION (US) | 2025-02-04 | — | — | US | disclosed |
| EP-4483187-A1 | A METHOD FOR DIAGNOSIS OF TRAUMATIC BRAIN INJURY | Medicortex Finland Oy (FI) | 2025-01-01 | — | — | EP | disclosed |
| EP-4457235-A1 | GLYCOMIMETIC LIGANDS | Aviceda Therapeutics, Inc. (US) | 2024-11-06 | — | — | EP | disclosed |
| US-RE50049-E1 | Compositions and methods for treating psoriasis | SYTHEON LTD. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240027460-A1 | IMMUNOMODULATORY CLINICAL BIOMARKER PROFILES AND USES THEREOF | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2023161557-A1 | A METHOD FOR DIAGNOSIS OF TRAUMATIC BRAIN INJURY | MEDICORTEX FINLAND OY (FI) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023129737-A1 | GLYCOMIMETIC LIGANDS | AVICEDA THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| US-20230128372-A1 | AZD1656 FOR USE IN THE TREATMENT OF PNEUMONITIS AND/OR MYCORDITIS CAUSED BY A CORONAVIRUS | EXCALIBUR MEDICINES LIMITED (GB) | 2023-04-27 | — | — | US | disclosed |
| US-20230065632-A1 | CYTOMETRIC ASSAYS | THE MEDICAL RESEARCH, INFRASTRUCTURE, AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER (IL) | 2023-03-02 | — | — | US | disclosed |
| EP-4117664-A1 | AZD1656 FOR USE IN THE TREATMENT OF PNEUMONITIS AND/OR MYCORDITIS CAUSED BY A CORONAVIRUS | Excalibur Medicines Limited (GB) | 2023-01-18 | — | — | EP | disclosed |
| CN-115551510-A | AZD1656 for the treatment of pneumonia and/or myocarditis caused by coronavirus | 埃克斯卡利伯医药有限公司 | 2022-12-30 | — | — | CN | disclosed |
| US-11480571-B2 | Cytometric assays | THE MEDICAL RESEARCH, INFRASTRUCTURE, AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER (IL) | 2022-10-25 | — | — | US | disclosed |
| WO-2022109340-A1 | IMMUNOMODULATORY CLINICAL BIOMARKER PROFILES AND USES THEREOF | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195689-A1 | GLYCOMIMETIC LIGANDS | SIGLEC9, SIGLEC7, LGALS2 | LGALS3 6/4885LGALS8 11/4885LGALS4 7/4885 |
| US-20230128372-A1 | AZD1656 FOR USE IN THE TREATMENT OF PNEUMONITIS AND/OR MYCORDITIS CAUSED BY A CORONAVIRUS | PIM1, MYC, PIM3 | LGALS3 534/4885LGALS8 512/4885LGALS4 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.